Medicines in the making
Institutions supported
Companies launched
Medicines in the clinic
Licenses to pharma
In addition to receiving funding, every scholar is paired with a results-oriented and mission-focused team from our Therapeutics Development Center. Teams consist of a project manager and experienced pharma and business development advisors with a track record of bringing new drugs to market.
Learn MoreOur pipeline represents the best science coming out of academic laboratories. Projects are selected for their innovation and potential for clinical impact. Our team proactively moves them forward to commercial viability and clinical use.
See All DiscoveriesBy concentrating philanthropic, scientific, and business development resources during the high-risk stages of drug development, Harrington ‘de-risks’ therapeutic candidates and positions them for further investment and commercialization.
Learn More
Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infants with few, if any, options for long-term survival
Continue Reading
Oxford, UK – 15th November 2024 – (or ‘the Company’, www.alveogene.com), a company focused on transforming rare...
Continue Reading
10 scientists have been selected for OHC’s first annual award to advance academic discoveries into clinical practice for rare diseases
Continue Reading
Lord Cameron will lead international efforts to drive the OHC’s mission of delivering 40 new therapies for rare diseases into clinical trials over the next ten years
Continue Reading